| Prev Close | 48.97 |
| Day Low/High | 49.01 / 49.45 |
| 52 Wk Low/High | 37.47 / 52.19 |
| Avg Volume | 1.72M |
Hologic Inc. (HOLX)
49.35
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 267.31M |
| Market Cap | 13.09B |
| EPS | -0.40 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Keep Buying the Dips in 2015
Underlying fundamentals are in place for a healthy stock market.
Making a List, Checking It Twice
Here's what we'd be buying into weakness for 2015.
Superior Management Makes a Huge Difference
Invest in companies whose management teams inspire confidence.
The Election Cycle Is Good for Stocks
Investing during a mid-term election can offer large returns.
Buy Into Those Fear-Driven Selloffs
There is a disconnect between stock prices and intrinsic value.
Everyone's Looking Up, but Should Be Looking Down
The Carl Icahn lesson. "Also-Ran Surprise No. 5: Carl Icahn's fund loses 15% to 20%." -- Kass Diary, 15 Surprises for 2014. By my calculation (below) Carl Icahn's portfolio (of individual stock holdings) has lost more than $6 billion from the recent...
Activists Push Stock Prices Higher
Corporate activism should continue to be a positive for stock prices.
Catching Up With Three Takeover Targets
Hologic, Symantec and TE Connectivity could all benefit from the current M&A binge.
Mergers and Acquisitions Are Back in Play
Spice up your portfolio with some takeover bait.
Slow-and-Steady Winners
Six stocks poised to deliver favorable returns for the balance of the year.
Time to Load Up on Hologic
Positive developments and an attractive entry point make the stock a table-pounding buy.
Updating the Market's Road Map
Buy the dips and don't chase the rallies.
That Was the Week That Was
Let's review.
Hologic Makes the Right Moves
They should improve shareholder value in coming months.
Icahn's Actions to Drive Hologic Higher
Hologic should benefit from a greater sense of urgency.
Passing on Hologic
Buying based on price in a mature bull market is not a recipe for success. Subscriber HG, thanks for the Stifel report on Hologic (HOLX). I am passing on this name as there appears to be no catalyst over the near term. Buying based on price in a mat...
From the Street of Dreams
Hologic's price target gets trimmed. Citigroup reiterates its neutral rating on Hologic (HOLX) but lowers its price target by $2 per share to $22. Staying away.
Hologic Reappears
After its miss, is it a value? Is there anyone on site who has a fundamental view of Hologic (HOLX)? This is an old name I have been long from in the past, and it used to be a large Omega Advisors holding. Prima facie, it looks like value despite th...
Diagnosis: Hologic
The health care company offers good value in this market.
